ResMed Inc
(STU:RME)
€
232.3
-1.9 (-0.81%)
Market Cap: 34.52 Bil
Enterprise Value: 34.92 Bil
PE Ratio: 32.70
PB Ratio: 6.98
GF Score: 98/100 Resmed Inc at Bank of America Merrill Lynch Global Healthcare Conference Transcript
Sep 19, 2019 / 10:25AM GMT
Release Date Price:
€119.1
(+2.32%)
Lyanne Harrison
BofA Merrill Lynch, Research Division - VP
Good morning, gentlemen, and welcome to our conversation with ResMed. I am Lyanne Harrison and I cover healthcare in Australia. And today, I have with me Robert Douglas; COO of ResMed; David Pendarvis, CAO; and Amy Wakeham, Head of Investor Relations.
So Rob, Dave, Amy, thank you for joining us and making your way to London.
David B. Pendarvis
ResMed Inc. - Chief Administrative Officer, Global General Counsel & Secretary
Thanks very much.
Robert A. Douglas
ResMed Inc. - President & COO
Thanks, Lyanne.
Lyanne Harrison
BofA Merrill Lynch, Research Division - VP
So for those of you who are not familiar with the ResMed story, I might get Rob to start with the presentation and an overview on ResMed.
Robert A. Douglas
ResMed Inc. - President & COO
Sure. Thanks, Lyanne. So we're just going to talk a little bit about ResMed's overall strategy in the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot